Easy and precise preventive vaccination
Vaccine shortages, workforce constraints, and the need for safer, more efficient vaccination remain global challenges. Idevax enables safe, accurate, and reliable intradermal vaccination, supporting the use of fractional vaccine doses while maintaining a strong immune response for selected vaccines. By helping extend vaccine supply and simplifying administration, our intradermal injection adaptor VAX-ID makes vaccination more accessible, efficient, and scalable.
Reliable prophylactic vaccination by Idevax
Fractional dosing
A fractional dose of 1/5th or even 1/10th of the full dose
Peer-reviewed studies
Non-inferior immune responses vs full dose IM
CE marked device
Can be used with approved vaccines
Global health impact
Solution to scale up immunizing 60-70% of the world’s population
Preventive vaccination saves millions of lives every year
Preventive (prophylactic) vaccination protects people before exposure to disease by training the immune system to recognize and fight pathogens. It remains one of the most cost-effective public health interventions, preventing an estimated 3.5 to 5 million deaths annually worldwide.
Intradermal injection is gaining recognition as an effective, dose-sparing vaccination method for diseases such as mpox, rabies, and polio. By delivering vaccines through the skin, it helps extend vaccine supply, improve access to immunization, and support large-scale vaccination programs that protect communities around the world.
Prophylactic vaccination: proven across major diseases
Read our peer-reviewed white papers on intradermal vaccination. Get to the heart of our applications and learn more about the science behind the intradermal route of administration for vaccines against following diseases:
Our solution for reliable preventive vaccination
VAX-ID is CE marked, MHRA registered intradermal injection adapter and suited for use with approved vaccines. Its penetration depth is predefined based on high-frequency ultrasound skin-thickness evaluations in adults, adolescents and children, ensuring accurate, consistent delivery into the dermal layer regardless of who administers it.
Lower
Vaccine dose needed
Lower
Pain & anxiety during injection
Lower
Training needs
Why dose-sparing prophylactic injection matters?
Future pandemics are inevitable, but vaccine production can’t always scale fast enough to reach 60–70% of the world’s population in time. Intradermal delivery offers a proven way to stretch supply without weakening protection.
Studies show a non-inferior immune response using only 1/5th to 1/10th vs. full-dose IM/SC injection, across Mpox, Hepatitis A/B, Influenza, Rabies, Polio, Yellow Fever and SARS-CoV-2.
Supporting dose-sparing strategies through preventive vaccination with VAX-ID
Idevax is advancing preventive vaccination through clinical research on intradermal fractional-dose vaccination, demonstrating its potential to reduce vaccine use while maintaining protection, improving vaccine access, affordability, and sustainability worldwide.
Our work includes the hepatitis B study by Van Mulder et al., which showed that fractional intradermal administration can induce robust immune responses while using substantially less vaccine compared to conventional intramuscular vaccination.
Furthermore, the rabies study by Soentjens et al. demonstrated the feasibility and immunogenicity of intradermal fractional dosing for pre-exposure rabies vaccination in healthy adults. The RABIKID study in children by Bracke et al. has recently finished enrolment. Stay tuned for results!
Interested in our solutions for preventive vaccination?
Talk to our team about integrating VAX-ID into your vaccination program or vaccine developments.
"*" indicates required fields